Jan 30 (Reuters) - Aeterna Zentaris Inc AEZ.TO
* Aeterna Zentaris announces completion of Zoptrex(TM) pivotal Phase 3 clinical trial in advanced endometrial cancer; expects to report top-line results in April 2017
* Aeterna Zentaris Inc - Currently expects to lock clinical database and to report top-line results in April 2017 for Phase 3 zoptec with zoptrex
* Aeterna Zentaris Inc - Occurrence of 384th death in pivotal phase 3 zoptec study with zoptrex Source text for Eikon: ID:nBw3nJBVLa Further company coverage: AEZ.TO